Jazz Pharmaceuticals Inc.'s stock closed Friday at $45.39 per share, up 9.49 percent.

The jump comes following the Palo Alto-based specialty pharmaceutical company (NASDAQ:JAZZ) saying Thursday it is expecting a larger profit in 2012, following its purchase of Azur Pharma Ltd. The deal witth Azur is expected to close the week of Jan. 16.

It also said sales of its narcolepsy drug, Xyrem, have done well.

"We were pleased with the strong performance of Xyrem in 2011, including 9 percent year-over-year volume growth in the fourth quarter and 11 percent volume growth for the full year, as we continue to invest in this important product," said Bruce Cozadd, the chairman and CEO of Jazz Pharmaceuticals in a prepared statement... (Source: bizjournals.com Health Care:Biotechnology headlines)

MedWorm Sponsor Message: Find the best January Sales in the UK.

More...